Dosing & Uses
Dosage Forms & Strengths
nasal spray
- 0.25%
- 0.5%
- 1%
Nasal Congestion
Instill 2-3 sprays or 2-3 gtt q4hr of 0.25-0.1% solution PRN; not to exceed 3 days
Dosage Forms & Strengths
nasal spray
- 0.25%
- 0.5%
- 1%
Nasal Congestion
<2 years
- Consult a physician
2-6 years
- 1-3 gtt intranasally q2-4hr of 0.125% solution PRN; not to exceed 3 days
6-12 years
- 2-3 gtt intranasally q4hr of 0.25% solution PRN; not to exceed 3 days
>12 years old
- Instill 1-2 sprays or 1-2 gtt intranasally q4hr of 0.25-0.1% solution PRN; not to exceed 3 days
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (1)
- zavegepant intranasal
phenylephrine nasal will decrease the level or effect of zavegepant intranasal by Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of intranasal decongestants with zavegepant intranasal. If unavoidable, administer intranasal decongestants at least 1 hr after zavegepant.
Monitor Closely (2)
- nicotine intranasal
phenylephrine nasal decreases levels of nicotine intranasal by Other (see comment). Use Caution/Monitor. Comment: Nasal vasoconstrictors prolong the time to peak concentrations by ~40% and decreases peak concentration by ~20%.
- safinamide
phenylephrine nasal and safinamide both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Monitor patients for hypertension if safinamide is prescribed concomitantly with prescription or nonprescription sympathomimetics, including nasal, oral, or ophthalmic decongestants and cold remedies.
Minor (0)
Adverse Effects
Frequency Not Defined
Stinging
Dryness
Rebound congestion
Sneezing
Burning
Warnings
Contraindications
Hypersensitivity to product or excipients
Use for >3 days
Cautions
Rebound congestion may occur
Temporary discomfort such as burning, stinging, sneezing, or an increase in nasal discharge may occur
Use of container by more than one person may spread infection
Use only as directed; frequent or prolonged use may cause nasal congestion to recur or worsen
Ask a healthcare professional before in heart disease, high blood pressure, thyroid disease, diabetes, trouble urinating due to an enlarged prostate gland
Stop use and ask healthcare professional if symptoms persist
Stop use if symptoms persist
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Alpha adrenergic agonist; stimulates alpha-adrenergic receptors in nasal conjunctiva and arterioles to produce vasoconstriction that results in nasal decongestion
Pharmacokinetics
Absorption: Minimal systemic
Duration: 2.5 - 4 hr
Onset: < 2 min
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Vazculep injection - | 10 mg/mL vial |  | |
| Vazculep injection - | 10 mg/mL vial |  | |
| Vazculep injection - | 10 mg/mL vial |  | |
| Vazculep injection - | 10 mg/mL vial |  | |
| Vazculep injection - | 10 mg/mL vial |  | |
| Wal-Four nasal - | 1 % liquid |  | |
| Wal-Four nasal - | 1 % liquid |  | |
| Neo-Synephrine (phenylephrine) nasal - | 1 % liquid |  | |
| Neo-Synephrine (phenylephrine) nasal - | 0.5 % liquid |  | |
| Neo-Synephrine (phenylephrine) nasal - | 0.25 % liquid |  | |
| Neo-Synephrine (phenylephrine) nasal - | 1 % liquid |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| phenylephrine injection - | 10 mg/mL vial |  | |
| Sinus Decongestant (PE) oral - | 10 mg tablet |  | |
| Sinus Decongestant (PE) oral - | 10 mg tablet |  | |
| Sinus Decongestant (PE) oral - | 10 mg tablet |  | |
| Sinus PE Decongestant oral - | 10 mg tablet |  | |
| Nasal Decongestant (phenylephrine) oral - | 10 mg tablet | | |
| Ephrine nasal - | 1 % drops |  | |
| Nasal Four nasal - | 1 % liquid |  | |
| Wal-phed PE oral - | 10 mg tablet | | |
| 4 Way nasal - | 1 % liquid |  | |
| phenylephrine ophthalmic (eye) - | 10 % drops |  | |
| phenylephrine ophthalmic (eye) - | 2.5 % drops |  | |
| phenylephrine ophthalmic (eye) - | 2.5 % drops |  | |
| phenylephrine ophthalmic (eye) - | 10 % drops |  | |
| phenylephrine ophthalmic (eye) - | 2.5 % drops |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
phenylephrine injection
NO MONOGRAPH AVAILABLE AT THIS TIME
USES: Consult your pharmacist.
HOW TO USE: Consult your pharmacist.
SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Consult your pharmacist.
DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: No monograph available at this time.
MISSED DOSE: Consult your pharmacist.
STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
Information last revised July 2016. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
